Status: Active
R3 Vascular
- Status Current
- Sector Peripheral Vascular
- Year Invested 2020
- HQ Mountain View, CA, United States & Munich, Germany
- Clinical Operations Austria, Italy, Canada
- Lead Partners Frederik Groenewegen
Website www.r3vascular.com/
Related News
- R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE Drug Eluting Bioresorbable Scaffold
- FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
- R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs
- R3 Vascular Inc Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO
- R3 Vascular Inc. Completes Series A Financing
Bioresorbable Scaffold Technology for Treatment of Peripheral Vascular Disease
R3 has developed a novel technology platform of fully bioresorbable vascular scaffolds with a sirolimus coating for treatment of Peripheral Artery Disease (PAD). The R3 Vascular platform combines the best of both worlds of below-the-knee (BTK) therapy, designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals.